When and how should subclinical hypothyroidism be treated with levothyroxine, including indications, initial dosing, dose adjustments, and monitoring?

Treatment of Subclinical Hypothyroidism

Levothyroxine treatment for subclinical hypothyroidism should be initiated when TSH is >10 mIU/L, in all pregnant women or those planning pregnancy regardless of TSH level, and may be considered for symptomatic patients with TSH 4.5-10 mIU/L after confirming persistent elevation on repeat testing. 1

When to Treat: TSH-Based Algorithm

TSH >10 mIU/L

• Treat with levothyroxine regardless of symptoms 1
• Progression rate to overt hypothyroidism is approximately 5% annually 1
• Treatment may prevent manifestations and consequences of hypothyroidism in those who progress 1

TSH 4.5-10 mIU/L

• Do not routinely treat - repeat thyroid function tests at 6-12 month intervals to monitor for improvement or worsening 1
• Evidence does not confirm clear benefits for early therapy compared with treatment when symptoms or overt hypothyroidism develop 1
• Consider a several-month trial only in symptomatic patients with clear hypothyroid symptoms 1
• Continuation of therapy should be predicated on clear symptomatic benefit; if no improvement after 3-4 months of normalized TSH, discontinue levothyroxine 1, 2
• The likelihood of symptomatic improvement is small and must be balanced against inconvenience, expense, and potential risks 1

Special Populations Requiring Treatment

Pregnancy and Women Planning Pregnancy:

• Treat all pregnant women or women planning pregnancy with elevated TSH to restore TSH to reference range, regardless of TSH level 1
• Based on possible association between high TSH and increased fetal wastage or neuropsychological complications in offspring 1
• Monitor TSH every 6-8 weeks during pregnancy and adjust dose as needed 1
• Levothyroxine requirements frequently increase during pregnancy 1

Patients Already on Levothyroxine:

• When subclinical hypothyroidism is noted in levothyroxine-treated patients with overt hypothyroidism, adjust dosage to bring TSH into reference range 1
• If TSH is in upper half of reference range and patient remains symptomatic, consider increasing dose to bring TSH to lower portion of reference range 1

Age-Specific Considerations

Elderly Patients (>65-70 years)

• Use caution - age-specific reference ranges for TSH should be considered 2
• For patients >80-85 years with TSH ≤10 mIU/L, adopt a wait-and-see strategy, generally avoiding hormonal treatment 2
• Treatment may be harmful in elderly patients with subclinical hypothyroidism 3
• TSH upper limit of normal is 7.5 mIU/L for patients over age 80 3

Younger Patients (<65 years)

• More likely to benefit from treatment, especially those with cardiovascular risk factors 4
• TSH upper limit of normal is 3.6 mIU/L for patients under age 40 3

Initial Dosing

Adults

• Full replacement dose: 1.6 mcg/kg/day for most young, healthy adults 5
• Lower starting doses (<1.6 mcg/kg/day) for:
  • Elderly patients 5
  • Patients at risk for atrial fibrillation 5
  • Patients with underlying cardiac disease 5, 6
  • Patients with long-standing severe hypothyroidism 6

Pregnant Women

• New onset hypothyroidism with TSH ≥10 IU/L: 1.6 mcg/kg/day 5
• New onset hypothyroidism with TSH <10 IU/L: 1.0 mcg/kg/day 5
• Pre-existing hypothyroidism: increase pre-pregnancy dose by 12.5-25 mcg/day 5

Dose Adjustments and Titration

General Population

• Titrate by 12.5-25 mcg increments every 4-6 weeks until patient is euthyroid 5
• For patients at risk for atrial fibrillation or with cardiac disease, titrate every 6-8 weeks 5
• Peak therapeutic effect may not be attained for 4-6 weeks 5

Target TSH Levels

• Adults: 0.4-2.5 mIU/L (lower half of reference range) 2
• Primary hypothyroidism: 0.5-2.0 mIU/L 6
• Pregnant patients: trimester-specific reference range 5

Monitoring

Initial Phase

• Check TSH 6-8 weeks after initiating therapy or any dose change in adults 5, 7
• Check TSH 2 months after starting therapy and adjust accordingly 2
• Pregnant patients: monitor TSH every 4 weeks until stable dose achieved 5

Maintenance Phase

• Once stable: monitor TSH at least annually 2, 7
• Stable patients: evaluate clinical and biochemical response every 6-12 months and whenever there is change in clinical status 5

Confirmation of Diagnosis Before Treatment

Critical Pitfall to Avoid

• 62% of elevated TSH levels may revert to normal spontaneously 3
• Repeat thyroid function tests ideally 2-3 months after initial abnormal result before initiating treatment 2, 3
• Measure both TSH and free T4, along with thyroid peroxidase antibodies 2
• Only 49.2% of treated patients had confirmatory testing before starting levothyroxine in one study, indicating common overtreatment 8

Risks of Treatment

• Subclinical hyperthyroidism may occur in 14-21% of treated individuals 1
• Over-replacement is associated with increased risk of atrial fibrillation and osteoporosis 6
• Treatment does not improve symptoms or cognitive function if TSH <10 mIU/L in double-blinded randomized controlled trials 3

When NOT to Treat

• Asymptomatic patients with TSH 4.5-10 mIU/L - insufficient evidence of benefit 1
• Patients >80-85 years with TSH ≤10 mIU/L - treatment may be harmful 2, 3
• Patients with single abnormal TSH without confirmatory testing - wait for repeat testing 2, 3